tradingkey.logo
tradingkey.logo
Suchen

Genfit SA

GNFT
Zur Watchlist hinzufügen
4.850USD
0.0000.00%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
741.27MMarktkapitalisierung
--KGV TTM

mehr Informationen über Genfit SA Unternehmen

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Genfit SA Informationen

BörsenkürzelGNFT
Name des UnternehmensGenfit SA
IPO-datumDec 19, 2006
CEOPrigent (Pascal)
Anzahl der mitarbeiter180
WertpapierartDepository Receipt
GeschäftsjahresendeDec 19
AddresseParc Eurasante 885 avenue Eugene Avinee
StadtLOOS
BörseNASDAQ OMX - NASDAQ BASIC
LandFrance
Postleitzahl59120
Telefon33320164000
Websitehttps://www.genfit.fr/
BörsenkürzelGNFT
IPO-datumDec 19, 2006
CEOPrigent (Pascal)

Führungskräfte von Genfit SA

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mrs. Anne-Helene Monsellato
Mrs. Anne-Helene Monsellato
Independent Director
Independent Director
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Eric Baclet
Mr. Eric Baclet
Independent Vice-Chairman of the Board of Directors
Independent Vice-Chairman of the Board of Directors
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Genfit SA?

Die fünf größten Anteilseigner von Genfit SA sind: Mr. Jean-Francois Mouney

Wie viele Institutionen halten Anteile an Genfit SA (GNFT)?

Mit Stand vom 2026Q1 halten 16 Institutionen Anteile an Genfit SA, mit einem Gesamtmarktwert von etwa 22.36K, was 0.04% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -215235.00 gestiegen.